Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × NSCLC × Bevacizumab × Clear all

Status

Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 51 Carcinoma, Non-Small-Cell Lung 26 Breast Neoplasms 17 Ovarian Neoplasms 13 Rectal Neoplasms 12 Neoplasm Metastasis 9 Glioblastoma 9 Carcinoma, Hepatocellular 9 Colonic Neoplasms 8 Carcinoma, Renal Cell 7 Uterine Cervical Neoplasms 6 Fallopian Tube Neoplasms 5 Brain Neoplasms 5 Triple Negative Breast Neoplasms 4 Nasopharyngeal Carcinoma 4 Stomach Neoplasms 3 Recurrence 3 Pleural Effusion, Malignant 3 Neoplasms 3 Meningeal Carcinomatosis 3 Melanoma 3 Lung Neoplasms 3 Kidney Neoplasms 3 Colorectal Cancer Metastatic 3 Non-squamous Non-small Cell Lung Cancer 2 Non-small Cell Lung Cancer Metastatic 2 Liver Neoplasms 2 Liver Metastasis Colon Cancer 2 Intestinal Neoplasms 2 Inflammatory Breast Neoplasms 2

Interventions

Gefitinib 5 icotinib 4 apatinib 3 anlotinib 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Docetaxel 3 osimertinib 2 dacomitinib 2 camrelizumab 2 aflutinib 2 Thalidomide 2 Drug Therapy 2 Carboplatin 2 Afatinib 2 spartalizumab 1 pembrolizumab 1 nimotuzumab 1 envafolimab 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Cisplatin 1 Bevacizumab 1 Axitinib 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04575415 2020-10-20

BELLA

Guangdong Association of Clinical Trials

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡